Nolvadex D (Tamoxifen Citrate)

Tamoxifen citrate, the active ingredient in Nolvadex D, is a selective estrogen receptor modulator presented as an oral tablet for oral use. It treats estrogen receptor‑positive breast cancer, helps prevent disease in high‑risk women, and is used for gynecomastia associated with certain conditions or therapies.

GNH USA supplies Nolvadex D as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Nolvadex D is a selective estrogen receptor modulator used in several estrogen‑driven conditions.

- Estrogen receptor‑positive breast cancer: reduces recurrence risk and controls disease progression. - High‑risk women for breast cancer prevention: lowers incidence of invasive breast cancer. - Gynecomastia associated with certain conditions or treatments: diminishes breast tissue growth and related discomfort.

Common Side Effects: - Hot flashes: transient feeling of warmth and sweating. - Nausea: mild to moderate upset stomach. - Fatigue: general tiredness or lack of energy. - Menstrual irregularities: changes in cycle length or flow.

Serious or Rare Side Effects: - Deep vein thrombosis or pulmonary embolism: blood clots in veins or lungs. - Endometrial cancer: abnormal growth of uterine lining. - Severe liver function abnormalities: elevated enzymes or hepatitis. - Life‑threatening allergic reactions: rash, swelling, or anaphylaxis.

Before initiating therapy, clinicians should assess individual risk factors and monitor relevant parameters. - Liver function monitoring: perform baseline and periodic liver enzyme tests. - Thromboembolic risk assessment: evaluate history of clotting disorders. - Uterine health evaluation: consider baseline gynecologic exam for endometrial risk. - Contraceptive counseling: advise on effective non‑estrogen contraception during treatment. - Store at ambient temperature: keep in original packaging, protect from moisture and heat.

Tamoxifen citrate may interact with several medicines; careful review is essential.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): reduce tamoxifen effectiveness. - CYP2D6‑inhibiting SSRIs (e.g., paroxetine, fluoxetine): lower active metabolite levels. - Warfarin: may increase anticoagulant effect and bleeding risk.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): may raise tamoxifen concentrations. - Other anticoagulants (e.g., heparin): require coagulation monitoring. - Herbal supplements such as St. John’s wort: potential induction of metabolism.